Download Supplementary References

Supplementary References
List 1
References found in PubMed, using a string “cardiac-specific overexpression” in the title.
Comments are shown in square brackets, repeated use of the same mouse line marked by color,
where known. All but two studies have an undefined transgene location. Comments on the list do
not distinguish the expression cassettes containing mouse αMHC promoter with human growth
hormone 3’-UTR , originally provided by Dr. Jeffrey Robbins, from those with SV40 T-antigen
3’-UTR, originally provided by Dr. Arthur Feldman. Three studies in the list used rat αMHC
promoter, originally available from Dr. Bernardo Nadal-Ginard.
1
2
3
4
5
6
7
8
9
10
Kolwicz SC, Jr., Odom GL, Nowakowski SG, Moussavi-Harami F, et al. 2016.
AAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances
Myocardial Contractility. Mol Ther 24: 240-50. [Not αMHC promoter]
Yang L, Gao JY, Ma J, Xu X, et al. 2015. Cardiac-specific overexpression of
metallothionein attenuates myocardial remodeling and contractile dysfunction in lNAME-induced experimental hypertension: Role of autophagy regulation. Toxicol Lett
237: 121-32. [αMHC promoter, Insertion site unknown, first described in 1997]
Liu Y, Shen Y, Zhu J, Liu M, et al. 2015. Cardiac-specific PID1 overexpression
enhances pressure overload-induced cardiac hypertrophy in mice. Cell Physiol Biochem
35: 1975-85. [αMHC promoter, insertion site unknown]
Cong W, Ruan D, Xuan Y, Niu C, et al. 2015. Cardiac-specific overexpression of
catalase prevents diabetes-induced pathological changes by inhibiting NF-kappaB
signaling activation in the heart. J Mol Cell Cardiol 89: 314-25. [αMHC promoter,
insertion site unknown, first described in 1996]
Xiang FL, Liu Y, Lu X, Jones DL, et al. 2014. Cardiac-specific overexpression of
human stem cell factor promotes epicardial activation and arteriogenesis after myocardial
infarction. Circ Heart Fail 7: 831-42.[Not αMHC promoter]
Pulinilkunnil T, Kienesberger PC, Nagendran J, Sharma N, et al. 2014. Cardiacspecific adipose triglyceride lipase overexpression protects from cardiac steatosis and
dilated cardiomyopathy following diet-induced obesity. Int J Obes (Lond) 38: 205-15.
[αMHC promoter, insertion site unknown, first described in 2012]
Huang Y, Wu D, Zhang X, Jiang M, et al. 2014. Cardiac-specific Traf2 overexpression
enhances cardiac hypertrophy through activating AKT/GSK3beta signaling. Gene 536:
225-31. [αMHC promoter, insertion site unknown]
Yang J, Mou Y, Wu T, Ye Y, et al. 2013. Cardiac-specific overexpression of farnesyl
pyrophosphate synthase induces cardiac hypertrophy and dysfunction in mice.
Cardiovasc Res 97: 490-9.[αMHC promoter, insertion site unknown]
Tang H, Xiao K, Mao L, Rockman HA, et al. 2013. Overexpression of TNNI3K, a
cardiac-specific MAPKKK, promotes cardiac dysfunction. J Mol Cell Cardiol 54: 10111. [αMHC promoter, insertion site unknown, first described in 2009].
Pollak NM, Schweiger M, Jaeger D, Kolb D, et al. 2013. Cardiac-specific
overexpression of perilipin 5 provokes severe cardiac steatosis via the formation of a
11
12
13
14
15
16
17
18
19
20
21
22
lipolytic barrier. J Lipid Res 54: 1092-102. [αMHC promoter, insertion site unknown,
uncommonly efficient overexpression]
Philip J, Xu Z, Bowles NE, Vallejo JG. 2013. Cardiac-specific overexpression of
melanoma differentiation-associated gene-5 protects mice from lethal viral myocarditis.
Circ Heart Fail 6: 326-34.[ αMHC promoter, insertion site unknown]
McCommis KS, Douglas DL, Krenz M, Baines CP. 2013. Cardiac-specific hexokinase
2 overexpression attenuates hypertrophy by increasing pentose phosphate pathway flux. J
Am Heart Assoc 2: e000355. [αMHC promoter, insertion site unknown]
Ma B, Xiong X, Chen C, Li H, et al. 2013. Cardiac-specific overexpression of CYP2J2
attenuates diabetic cardiomyopathy in male streptozotocin-induced diabetic mice.
Endocrinology 154: 2843-56. [αMHC promoter, insertion site unknown, strain described
in 2004, ref.#56]
Hu N, Han X, Lane EK, Gao F, et al. 2013. Cardiac-specific overexpression of
metallothionein rescues against cigarette smoking exposure-induced myocardial
contractile and mitochondrial damage. PLoS One 8: e57151. [αMHC promoter, insertion
site unknown ,line described in 1997, the same as in ref 2]
Turdi S, Han X, Huff AF, Roe ND, et al. 2012. Cardiac-specific overexpression of
catalase attenuates lipopolysaccharide-induced myocardial contractile dysfunction: role
of autophagy. Free Radic Biol Med 53: 1327-38. [αMHC promoter, insertion site
unknown, line described in 1996, the same as in ref 4]
Toib A, Zhang HX, Broekelmann TJ, Hyrc KL, et al. 2012. Cardiac specific ATPsensitive K+ channel (KATP) overexpression results in embryonic lethality. J Mol Cell
Cardiol 53: 437-45.[aMHC, line described in 2001 [αMHC promoter, insertion site
unknown, line described in 2001]
Pott C, Muszynski A, Ruhe M, Bogeholz N, et al. 2012. Proarrhythmia in a non-failing
murine model of cardiac-specific Na+/Ca 2+ exchanger overexpression: whole heart and
cellular mechanisms. Basic Res Cardiol 107: 247.[ αMHC promoter, insertion site
unknown, line described in 1997]
Kandadi MR, Yu X, Frankel AE, Ren J. 2012. Cardiac-specific catalase
overexpression rescues anthrax lethal toxin-induced cardiac contractile dysfunction: role
of oxidative stress and autophagy. BMC Med 10: 134. . [αMHC promoter, insertion site
unknown, line described in 1996, the same as in ref 4]
Zhang Y, Zeng Y, Wang M, Tian C, et al. 2011. Cardiac-specific overexpression of E3
ligase Nrdp1 increases ischemia and reperfusion-induced cardiac injury. Basic Res
Cardiol 106: 371-83.[αMHC promoter, insertion site unknown]
Yan L, Wei X, Tang QZ, Feng J, et al. 2011. Cardiac-specific mindin overexpression
attenuates cardiac hypertrophy via blocking AKT/GSK3beta and TGF-beta1-Smad
signalling. Cardiovasc Res 92: 85-94.[ αMHC promoter, insertion site unknown]
Reinartz M, Molojavyi A, Moellendorf S, Hohlfeld T, et al. 2011. beta-Adrenergic
signaling and response to pressure overload in transgenic mice with cardiac-specific
overexpression of inducible NO synthase. Nitric Oxide 25: 11-21. .[ αMHC promoter,
insertion site unknown, 17 lines generated, line described in 2002, maximal expression
had no morbid phenotype]
Lu S, Crawford GL, Dore J, Anderson SA, et al. 2011. Cardiac-specific NRAP
overexpression causes right ventricular dysfunction in mice. Exp Cell Res 317: 1226-37.
.[not αMHC promoter]
23
24
25
26
27
28
29
30
31
32
33
Hu N, Guo R, Han X, Zhu B, et al. 2011. Cardiac-specific overexpression of
metallothionein rescues nicotine-induced cardiac contractile dysfunction and interstitial
fibrosis. Toxicol Lett 202: 8-14. [αMHC promoter, insertion site unknown ,line described
in 1997, the same as in ref 2].
Horikawa YT, Panneerselvam M, Kawaraguchi Y, Tsutsumi YM, et al. 2011.
Cardiac-specific overexpression of caveolin-3 attenuates cardiac hypertrophy and
increases natriuretic peptide expression and signaling. J Am Coll Cardiol 57: 2273-83.
[αMHC promoter, insertion site unknown , line described in 2008, ref. 36]
Ge ZD, Ionova IA, Vladic N, Pravdic D, et al. 2011. Cardiac-specific overexpression of
GTP cyclohydrolase 1 restores ischaemic preconditioning during hyperglycaemia.
Cardiovasc Res 91: 340-9. .[αMHC promoter, insertion site unknown].
Zhang X, Min X, Li C, Benjamin IJ, et al. 2010. Involvement of reductive stress in the
cardiomyopathy in transgenic mice with cardiac-specific overexpression of heat shock
protein 27. Hypertension 55: 1412-7. [αMHC promoter, insertion site unknown, line
described in 2007].
Xue W, Cai L, Tan Y, Thistlethwaite P, et al. 2010. Cardiac-specific overexpression of
HIF-1{alpha} prevents deterioration of glycolytic pathway and cardiac remodeling in
streptozotocin-induced diabetic mice. Am J Pathol 177: 97-105. [αMHC promoter,
insertion site unknown, line described in 2005].
Watson PA, Birdsey N, Huggins GS, Svensson E, et al. 2010. Cardiac-specific
overexpression of dominant-negative CREB leads to increased mortality and
mitochondrial dysfunction in female mice. Am J Physiol Heart Circ Physiol 299: H205668. [αMHC promoter, insertion site unknown, line described in 1997].
Timofeyev V, Porter CA, Tuteja D, Qiu H, et al. 2010. Disruption of adenylyl cyclase
type V does not rescue the phenotype of cardiac-specific overexpression of proteininduced cardiomyopathy. Am J Physiol Heart Circ Physiol 299: H1459-67. [αMHC
promoter for Galphaq, insertion site unknown, line described in 1997]
Qin F, Lennon-Edwards S, Lancel S, Biolo A, et al. 2010. Cardiac-specific
overexpression of catalase identifies hydrogen peroxide-dependent and -independent
phases of myocardial remodeling and prevents the progression to overt heart failure in
G(alpha)q-overexpressing transgenic mice. Circ Heart Fail 3: 306-13. [αMHC promoter
for both Galphaq and catalase, insertion sites unknown, lines described in 1996 (the same
as in ref 4) and 1997 (D’Angelo) ]
Ge W, Zhang Y, Han X, Ren J. 2010. Cardiac-specific overexpression of catalase
attenuates paraquat-induced myocardial geometric and contractile alteration: role of ER
stress. Free Radic Biol Med 49: 2068-77. [αMHC promoter, insertion sites unknown, line
described in 1996, the same as in ref 4
Barreto F, Rezende DC, Scaramello CB, Silva CL, et al. 2010. Lack of evidence for
regulation of cardiac P-type ATPases and MAP kinases in transgenic mice with cardiacspecific overexpression of constitutively active alpha(1B)-adrenoceptors. Braz J Med
Biol Res 43: 500-5. [αMHC promoter, insertion site unknown, line described in 1994]
Zhao P, Turdi S, Dong F, Xiao X, et al. 2009. Cardiac-specific overexpression of
insulin-like growth factor I (IGF-1) rescues lipopolysaccharide-induced cardiac
dysfunction and activation of stress signaling in murine cardiomyocytes. Shock 32: 1007. [unlike most others, uses a shorter rat αMHC promoter, insertion site unknown, line
described in 1996]
34
35
36
37
38
39
40
41
42
43
44
45
Xiong D, Wang GX, Burkin DJ, Yamboliev IA, et al. 2009. Cardiac-specific
overexpression of the human short CLC-3 chloride channel isoform in mice. Clin Exp
Pharmacol Physiol 36: 386-93. . [αMHC promoter, insertion site unknown]
Yano N, Tseng A, Zhao TC, Robbins J, et al. 2008. Temporally controlled
overexpression of cardiac-specific PI3Kalpha induces enhanced myocardial contractility-a new transgenic model. Am J Physiol Heart Circ Physiol 295: H1690-4. [modified
αMHC promoter, containing seven repeats of the tetO sequences adjacent to the TATA
box, insertion site unknown]
Tsutsumi YM, Horikawa YT, Jennings MM, Kidd MW, et al. 2008. Cardiac-specific
overexpression of caveolin-3 induces endogenous cardiac protection by mimicking
ischemic preconditioning. Circulation 118: 1979-88. [αMHC promoter, insertion site
unknown]
Rivard K, Paradis P, Nemer M, Fiset C. 2008. Cardiac-specific overexpression of the
human type 1 angiotensin II receptor causes delayed repolarization. Cardiovasc Res 78:
53-62. [αMHC promoter, insertion site unknown, line described in 1999]
Lai ZF, Chen YZ, Feng LP, Meng XM, et al. 2008. Overexpression of TNNI3K, a
cardiac-specific MAP kinase, promotes P19CL6-derived cardiac myogenesis and
prevents myocardial infarction-induced injury. Am J Physiol Heart Circ Physiol 295:
H708-16. [false search hit]
Zhang T, Yong SL, Tian XL, Wang QK. 2007. Cardiac-specific overexpression of
SCN5A gene leads to shorter P wave duration and PR interval in transgenic mice.
Biochem Biophys Res Commun 355: 444-50. [αMHC promoter, insertion site unknown]
Wu S, Li Q, Du M, Li SY, et al. 2007. Cardiac-specific overexpression of catalase
prolongs lifespan and attenuates ageing-induced cardiomyocyte contractile dysfunction
and protein damage. Clin Exp Pharmacol Physiol 34: 81-7. [αMHC promoter, insertion
site unknown, line described in 1996 (Kang)]
Niizeki T, Takeishi Y, Arimoto T, Takahashi H, et al. 2007. Cardiac-specific
overexpression of diacylglycerol kinase zeta attenuates left ventricular remodeling and
improves survival after myocardial infarction. Am J Physiol Heart Circ Physiol 292:
H1105-12. [αMHC promoter, insertion site unknown, line described in 2005 ]
Li Q, Wu S, Li SY, Lopez FL, et al. 2007. Cardiac-specific overexpression of insulinlike growth factor 1 attenuates aging-associated cardiac diastolic contractile dysfunction
and protein damage. Am J Physiol Heart Circ Physiol 292: H1398-403. [unlike most
others, uses a shorter rat αMHC promoter, insertion site unknown, line described in 1996]
Li Q, Ren J. 2007. Influence of cardiac-specific overexpression of insulin-like growth
factor 1 on lifespan and aging-associated changes in cardiac intracellular Ca2+
homeostasis, protein damage and apoptotic protein expression. Aging Cell 6: 799-806.
[unlike most others, uses a shorter rat αMHC promoter, insertion site unknown, line
described in 1996]
House SL, Melhorn SJ, Newman G, Doetschman T, et al. 2007. The protein kinase C
pathway mediates cardioprotection induced by cardiac-specific overexpression of
fibroblast growth factor-2. Am J Physiol Heart Circ Physiol 293: H354-65. [αMHC
promoter, insertion site unknown, line described in 2003 ]
Ceci M, Gallo P, Santonastasi M, Grimaldi S, et al. 2007. Cardiac-specific
overexpression of E40K active Akt prevents pressure overload-induced heart failure in
46
47
48
49
50
51
52
53
54
55
56
57
mice by increasing angiogenesis and reducing apoptosis. Cell Death Differ 14: 1060-2.
[αMHC promoter, insertion site unknown, line described in 2004]
Nishikawa K, Yoshida M, Kusuhara M, Ishigami N, et al. 2006. Left ventricular
hypertrophy in mice with a cardiac-specific overexpression of interleukin-1. Am J Physiol
Heart Circ Physiol 291: H176-83. [αMHC promoter, insertion site unknown]
Gramolini AO, Trivieri MG, Oudit GY, Kislinger T, et al. 2006. Cardiac-specific
overexpression of sarcolipin in phospholamban null mice impairs myocyte function that
is restored by phosphorylation. Proc Natl Acad Sci U S A 103: 2446-51. [αMHC
promoter, construct targeted to the Hprt locus, line described I 2004, ref #58]
Arimoto T, Takeishi Y, Takahashi H, Shishido T, et al. 2006. Cardiac-specific
overexpression of diacylglycerol kinase zeta prevents Gq protein-coupled receptor
agonist-induced cardiac hypertrophy in transgenic mice. Circulation 113: 60-6. [αMHC
promoter, insertion site unknown]
Zhai P, Yamamoto M, Galeotti J, Liu J, et al. 2005. Cardiac-specific overexpression of
AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and
bradycardia in transgenic mice. J Clin Invest 115: 3045-56. [αMHC promoter, insertion
site unknown]
Saba S, Janczewski AM, Baker LC, Shusterman V, et al. 2005. Atrial contractile
dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to
cardiac-specific overexpression of tumor necrosis factor-{alpha}. Am J Physiol Heart
Circ Physiol 289: H1456-67.[αMHC promoter, insertion site unknown, line described in
1997, ref #79]
Park SY, Cho YR, Finck BN, Kim HJ, et al. 2005. Cardiac-specific overexpression of
peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and
liver. Diabetes 54: 2514-24. .[αMHC promoter, insertion site unknown, line described in
2002].
Kadokami T, McTiernan CF, Higuichi Y, Frye CS, et al. 2005. 17 Beta-estradiol
improves survival in male mice with cardiomyopathy induced by cardiac-specific tumor
necrosis factor-alpha overexpression. J Interferon Cytokine Res 25: 254-60.[αMHC
promoter, insertion site unknown, line described in 1997, ref #79]
House SL, Branch K, Newman G, Doetschman T, et al. 2005. Cardioprotection
induced by cardiac-specific overexpression of fibroblast growth factor-2 is mediated by
the MAPK cascade. Am J Physiol Heart Circ Physiol 289: H2167-75. [αMHC promoter,
insertion site unknown, line described in 2003]
Hoffmann S. 2005. Cardiac-specific overexpression of angiotensin II type 1 receptor in
transgenic rats. Methods Mol Med 112: 389-403. [αMHC promoter, insertion site
unknown]
Crawford M, Ford S, Henry M, Matherne GP, et al. 2005. Myocardial function
following cold ischemic storage is improved by cardiac-specific overexpression of A1adenosine receptors. Can J Physiol Pharmacol 83: 493-8. [αMHC promoter with MEF2
mutation, insertion site unknown, line described in 1997]
Xiao YF, Ke Q, Seubert JM, Bradbury JA, et al. 2004. Enhancement of cardiac L-type
Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2. Mol
Pharmacol 66: 1607-16. [αMHC promoter, insertion site unknown].
Benoit MJ, Rindt H, Allen BG. 2004. Cardiac-specific transgenic overexpression of
alpha1B-adrenergic receptors induce chronic activation of ERK MAPK signalling.
58
59
60
61
62
63
64
65
66
67
68
Biochem Cell Biol 82: 719-27. [αMHC promoter, insertion site unknown, line described
in 1997].
Asahi M, Otsu K, Nakayama H, Hikoso S, et al. 2004. Cardiac-specific overexpression
of sarcolipin inhibits sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA2a) activity
and impairs cardiac function in mice. Proc Natl Acad Sci U S A 101: 9199-204. [αMHC
promoter, construct targeted to the Hprt locus] Note: there is a non-targeted transgene by
Babu (2006).
Zhang X, Klein AL, Alberle NS, Norby FL, et al. 2003. Cardiac-specific
overexpression of catalase rescues ventricular myocytes from ethanol-induced cardiac
contractile defect. J Mol Cell Cardiol 35: 645-52. [αMHC promoter, insertion site
unknown, line described in 1996 (Kang)]
Nakayama H, Otsu K, Yamaguchi O, Nishida K, et al. 2003. Cardiac-specific
overexpression of a high Ca2+ affinity mutant of SERCA2a attenuates in vivo pressure
overload cardiac hypertrophy. FASEB J 17: 61-3. [αMHC promoter, insertion site
unknown, no overexpression at 10 weeks].
House SL, Bolte C, Zhou M, Doetschman T, et al. 2003. Cardiac-specific
overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and
infarction in a murine model of low-flow ischemia. Circulation 108: 3140-8. [αMHC
promoter, insertion site unknown]
Hasseldine AR, Harper EA, Black JW. 2003. Cardiac-specific overexpression of
human beta2 adrenoceptors in mice exposes coupling to both Gs and Gi proteins. Br J
Pharmacol 138: 1358-66. [αMHC promoter, insertion site unknown, line described in
1994 (Milano)].
Liu X, Callaerts-Vegh Z, Evans KL, Bond RA. 2002. Chronic infusion of betaadrenoceptor antagonist and inverse agonists decreases elevated protein kinase A activity
in transgenic mice with cardiac-specific overexpression of human beta 2-adrenoceptor. J
Cardiovasc Pharmacol 40: 448-55. [αMHC promoter, insertion site unknown, line
described in 1994 (Milano)]
Liao R, Jain M, Cui L, D'Agostino J, et al. 2002. Cardiac-specific overexpression of
GLUT1 prevents the development of heart failure attributable to pressure overload in
mice. Circulation 106: 2125-31. [αMHC promoter, insertion site unknown, high apparent
over expression without overt phenotype]
Heger J, Godecke A, Flogel U, Merx MW, et al. 2002. Cardiac-specific overexpression
of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ Res
90: 93-9. [αMHC promoter, insertion site unknown, high apparent over expression
without overt phenotype]
Black RG, Jr., Guo Y, Ge ZD, Murphree SS, et al. 2002. Gene dosage-dependent
effects of cardiac-specific overexpression of the A3 adenosine receptor. Circ Res 91:
165-72. [αMHC promoter, insertion site unknown, high copy number not tolerated]
Zhang X, Azhar G, Chai J, Sheridan P, et al. 2001. Cardiomyopathy in transgenic
mice with cardiac-specific overexpression of serum response factor. Am J Physiol Heart
Circ Physiol 280: H1782-92. [αMHC promoter, insertion site unknown, high copy
number not tolerated]
Liao HS, Kang PM, Nagashima H, Yamasaki N, et al. 2001. Cardiac-specific
overexpression of cyclin-dependent kinase 2 increases smaller mononuclear
69
70
71
72
73
74
75
76
77
78
cardiomyocytes. Circ Res 88: 443-50. [αMHC promoter, insertion site unknown,
relatively high expression, no adverse phenotype]
Zhai J, Schmidt AG, Hoit BD, Kimura Y, et al. 2000. Cardiac-specific overexpression
of a superinhibitory pentameric phospholamban mutant enhances inhibition of cardiac
function in vivo. J Biol Chem 275: 10538-44. [αMHC promoter, insertion site unknown,
no “over” expression].
Schmidt AG, Kadambi VJ, Ball N, Sato Y, et al. 2000. Cardiac-specific overexpression
of calsequestrin results in left ventricular hypertrophy, depressed force-frequency relation
and pulsus alternans in vivo. J Mol Cell Cardiol 32: 1735-44. [αMHC promoter, insertion
site unknown, line described in 1998, 20-fold overexpression, induction of “fetal” genes,
but only mild hyperthrophy]
Li X, Moody MR, Engel D, Walker S, et al. 2000. Cardiac-specific overexpression of
tumor necrosis factor-alpha causes oxidative stress and contractile dysfunction in mouse
diaphragm. Circulation 102: 1690-6.[αMHC promoter, insertion site unknown, line is
different from that in ref #79, authors found gross diaphragm dysfunction]
Yatani A, Frank K, Sako H, Kranias EG, et al. 1999. Cardiac-specific overexpression
of Galphaq alters excitation-contraction coupling in isolated cardiac myocytes. J Mol Cell
Cardiol 31: 1327-36. [αMHC promoter, insertion site unknown, line described in 1997
(D’Angelo]]
Small K, Feng JF, Lorenz J, Donnelly ET, et al. 1999. Cardiac specific overexpression
of transglutaminase II (G(h)) results in a unique hypertrophy phenotype independent of
phospholipase C activation. J Biol Chem 274: 21291-6. [αMHC promoter, insertion site
unknown, partial activation of “fetal” genes]
Sah VP, Minamisawa S, Tam SP, Wu TH, et al. 1999. Cardiac-specific overexpression
of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. J
Clin Invest 103: 1627-34. [αMHC promoter, insertion site unknown, prominent atrial
dysfunction]
Muth JN, Yamaguchi H, Mikala G, Grupp IL, et al. 1999. Cardiac-specific
overexpression of the alpha(1) subunit of the L-type voltage-dependent Ca(2+) channel in
transgenic mice. Loss of isoproterenol-induced contraction. J Biol Chem 274: 21503-6.
[αMHC promoter, insertion site unknown, lines that did not die initially, were used]
Sato Y, Ferguson DG, Sako H, Dorn GW, 2nd, et al. 1998. Cardiac-specific
overexpression of mouse cardiac calsequestrin is associated with depressed
cardiovascular function and hypertrophy in transgenic mice. J Biol Chem 273: 28470-7.
[αMHC promoter, insertion site unknown, 20-fold overexpression, induction of “fetal”
genes, but only mild hyperthrophy]
Masaki H, Kurihara T, Yamaki A, Inomata N, et al. 1998. Cardiac-specific
overexpression of angiotensin II AT2 receptor causes attenuated response to AT1
receptor-mediated pressor and chronotropic effects. J Clin Invest 101: 527-35. [αMHC
promoter, insertion site unknown, minimal documentation on copy number and
expression]
Lemire I, Allen BG, Rindt H, Hebert TE. 1998. Cardiac-specific overexpression of
alpha1BAR regulates betaAR activity via molecular crosstalk. J Mol Cell Cardiol 30:
1827-39. [αMHC promoter, insertion site unknown, line described in 1997 (Akhter), but
their lines “were bred for higher expression” by the authors]
79
80
81
Kubota T, McTiernan CF, Frye CS, Slawson SE, et al. 1997. Dilated cardiomyopathy
in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha.
Circ Res 81: 627-35. [αMHC promoter, insertion site unknown, a remake with adifferent
construct from # 80]
Kubota T, McTiernan CF, Frye CS, Demetris AJ, et al. 1997. Cardiac-specific
overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic
mice. J Card Fail 3: 117-24. [αMHC promoter, insertion site unknown, 3 mice died
within 11 days after birth]
Kadambi VJ, Ponniah S, Harrer JM, Hoit BD, et al. 1996. Cardiac-specific
overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte
mechanics in transgenic mice. J Clin Invest 97: 533-9. [αMHC promoter, two lines,
insertion site unknown, only 2-fold overexpression and mild phenotype, used as ref. 22 in
the main text]
List 2
References found in PubMed, using a string “cardiomocyte-specific overexpression” in
the title. Comments are shown in square brackets, repeated use of the same mouse line marked
by color, where known.
1
2
3
4
5
6
7
Basheer WA, Harris BS, Mentrup HL, Abreha M, et al. 2015. Cardiomyocytespecific overexpression of the ubiquitin ligase Wwp1 contributes to reduction in
Connexin 43 and arrhythmogenesis. J Mol Cell Cardiol 88: 1-13. [bipartite inducible
expression with cre under αMHC promoter, insertion site unknown]
Bloch KD, Janssens S. 2005. Cardiomyocyte-specific overexpression of nitric oxide
synthase 3: impact on left ventricular function and myocardial infarction. Trends
Cardiovasc Med 15: 249-53.[review on NOS3 eoverexpression]
Duerr GD, Heinemann JC, Arnoldi V, Feisst A, et al. 2014. Cardiomyocyte specific
peroxisome proliferator-activated receptor-alpha overexpression leads to irreversible
damage in ischemic murine heart. Life Sci 102: 88-97. [αMHC promoter, several lines, up
to 135-fold overexpression, no effect on life span, insertion sites unknown, line described
in 2002 (Finck et al)]
Elrod JW, Greer JJ, Bryan NS, Langston W, et al. 2006. Cardiomyocyte-specific
overexpression of NO synthase-3 protects against myocardial ischemia-reperfusion
injury. Arterioscler Thromb Vasc Biol 26: 1517-23.[native eNOS promoter]
Favre J, Gao J, Zhang AD, Remy-Jouet I, et al. 2011. Coronary endothelial
dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. Am
J Physiol Heart Circ Physiol 300: H2035-43. [bipartite inducible expression system, with
aMHC-rTA, main gene insertion site unknown, line described in 2005].
Ichinose F, Buys ES, Neilan TG, Furutani EM, et al. 2007. Cardiomyocyte-specific
overexpression of nitric oxide synthase 3 prevents myocardial dysfunction in murine
models of septic shock. Circ Res 100: 130-9. [αMHC promoter, insertion site unknown,
line described in 2004(ref #7)
Janssens S, Pokreisz P, Schoonjans L, Pellens M, et al. 2004. Cardiomyocyte-specific
overexpression of nitric oxide synthase 3 improves left ventricular performance and
8
9
10
11
12
13
14
15
16
17
reduces compensatory hypertrophy after myocardial infarction. Circ Res 94: 1256-62.
[αMHC promoter, insertion site unknown]
Kim T, Zhelyabovska O, Liu J, Yang Q. 2013. Generation of an inducible,
cardiomyocyte-specific transgenic mouse model with PPAR beta/delta overexpression.
Methods Mol Biol 952: 57-65. [binary inducible expression system, with αMHC-cre,
main gene insertion site unknown]
Murata K, Ishida J, Ishimaru T, Mizukami H, et al. 2016. Lactation is a Risk Factor
of Postpartum Heart Failure in Mice with Cardiomyocyte-specific Apelin Receptor (APJ)
Overexpression. J Biol Chem. [αMHC promoter, insertion site unknown]
Nagendran J, Kienesberger PC, Pulinilkunnil T, Zordoky BN, et al. 2013.
Cardiomyocyte specific adipose triglyceride lipase overexpression prevents doxorubicin
induced cardiac dysfunction in female mice. Heart 99: 1041-7.) [αMHC promoter,
insertion site unknown, line described in 2011, unlike others, construct contains β-globin
3’-UTR]
Schuster I, Mahmoodzadeh S, Dworatzek E, Jaisser F, et al. 2016. Cardiomyocytespecific overexpression of oestrogen receptor beta improves survival and cardiac function
after myocardial infarction in female and male mice. Clin Sci (Lond) 130: 365-76.[binary
inducible system, based on αMHC-rTA combined with targeting of the main gene to aspecific locus ]
Talukder MA, Elnakish MT, Yang F, Nishijima Y, et al. 2013. Cardiomyocytespecific overexpression of an active form of Rac predisposes the heart to increased
myocardial stunning and ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol
304: H294-302. [αMHC promoter drives expression of a plant gene, insertion site
unknown]
Tanaka M, Nakae S, Terry RD, Mokhtari GK, et al. 2004. Cardiomyocyte-specific
Bcl-2 overexpression attenuates ischemia-reperfusion injury, immune response during
acute rejection, and graft coronary artery disease. Blood 104: 3789-96. [aMHC promoter,
insertion site unknown]
Wang H, Sreenivasan U, Gong DW, O'Connell KA, et al. 2013. Cardiomyocytespecific perilipin 5 overexpression leads to myocardial steatosis and modest cardiac
dysfunction. J Lipid Res 54: 953-65. [αMHC promoter, insertion site unknown]
Xiang FL, Lu X, Hammoud L, Zhu P, et al. 2009. Cardiomyocyte-specific
overexpression of human stem cell factor improves cardiac function and survival after
myocardial infarction in mice. Circulation 120: 1065-74, 9 p following 74. [bipartite
αMHC system (Sanbe et al), insertion site of the main gene unknown]
Xiang FL, Lu X, Liu Y, Feng Q. 2013. Cardiomyocyte-specific overexpression of
human stem cell factor protects against myocardial ischemia and reperfusion injury. Int J
Cardiol 168: 3486-94. [bipartite αMHC system (Sanbe, as in ref.16), insertion site of the
main gene unknown]
Yoshikawa N, Shimizu N, Maruyama T, Sano M, et al. 2012. Cardiomyocyte-specific
overexpression of HEXIM1 prevents right ventricular hypertrophy in hypoxia-induced
pulmonary hypertension in mice. PLoS One 7: e52522. [false hit, not a transgenic mouse]